0.25
0.5
0.75
1.25
1.5
1.75
2
Masitinib for the treatment of amyotrophic lateral sclerosis (ALS): preclinical overview
Published on Jul 21, 20171114 Views
Masitinib is a selective oral tyrosine kinase inhibitor targeting CSF1R and c-Kit. Clinical data from the phase 3 study (AB10015) of masitinib in amyotrophic lateral sclerosis (ALS) demonstrated a cl
Related categories
Chapter list
Masitinib for the treatment of amyotrophic lateral sclerosis (ALS)00:00
Acknowledgments00:25
Summary of recent clinical findings for masitinib in ALS01:10
Why post-paralysis tyrosine kinase inhibition in ALS?02:08
Isolation and characterization of aberrant glial cells (AbAs)05:24
Identification of aberant glial cells in the degenerating spinal cord06:41
AbA proliferation after paralysis onset07:35
Masitinib as a prototypic inhibitor of type III growth factor receptors08:02
Masitinib treatment after paralysis onset increases survival of SOD1G93A rats09:46
Hindlimb paralysis onset (day 1)11:14
Reduction of microgliosis and aberrant glial cells through CSF-1R inhibition13:00
Masitinib prevents motor neuron degeneration13:47
Alternative cellular targets for masitinib in the PNS16:22
Mast cells cluster together with motor nerve endings and macrophages in EDL muscle - 117:25
Mast cells cluster together with motor nerve endings and macrophages in EDL muscle - 219:16
Masitinib prevents mast cell and macrophage infiltration in the PNS21:29
Masitinib prevents Schwann cells and vascular remodeling23:00
Masitinib reduces mast cells accumulation in the sciatic nerve25:38
Masitinib reduces macrophages infiltration26:41
Conclusions 127:09
Conclusions 28:39
Thanks !!30:01